This antibody-drug Ozogamicin represents a unique breakthrough in the management of relapsed myeloblastic malignancy, specifically relapsed blood leukemia (AML). This antibody-drug joins a monoclonal protein specific https://socialmediainuk.com/story26670644/gemtuzumab-oz-ozogamicin-a-full-review